FDA Approves First mRNA Seasonal Influenza Vaccine for Seniors

On September 13, 2026, the U.S. Food and Drug Administration (FDA) approved Moderna’s mFlusiva (mRNA-1010), making it the first mRNA-based seasonal influenza vaccine for adults aged 50 years and older. The decision was supported by results from the Phase 3 FLUENT trial, which involved 40,703 participants. The trial demonstrated that the vaccine was both noninferior and superior to traditional standard-dose vaccines, showing a relative efficacy of 26.6%. Set for use during the 2026-2027 flu season, mFlusiva is intended to strengthen flu prevention for older adults, who are more susceptible to severe complications. Most adverse events reported during the trial were mild to moderate, indicating a favorable safety profile. The approval marks a transition for mRNA technology into routine immunization.

The development of mFlusiva utilizes the same mRNA technology that rose to prominence during the COVID-19 pandemic. While traditional influenza vaccines often use weakened or inactivated viruses to trigger an immune response, mRNA vaccines work by instructing cells to make a protein that mimics a piece of the virus. This allows the body to build an immune defense without using the live virus itself. Historically, influenza has caused significant illness and death, particularly among older people, making the availability of effective vaccines a public health priority. Data from the FLUENT trial suggests mFlusiva provides enhanced protection, which is vital for managing annual seasonal outbreaks.

Implementing mFlusiva effectively will require cooperation between healthcare providers, public health officials, and community groups. Education and outreach are central to reaching older adults, providing them with information on the vaccine's role and addressing any questions they may have. Healthcare providers will also need the necessary tools and information to discuss the new vaccine with their patients. These collaborative efforts are intended to raise vaccination rates and improve health outcomes by reducing the frequency of influenza among the older population.

The approval of mFlusiva is also expected to have broader economic effects. By lowering the incidence of influenza in older adults, the vaccine may help reduce healthcare spending on hospitalizations, medical treatments, and productivity lost to illness. Furthermore, successful vaccination programs can help maintain public trust in immunization, which is an important factor in addressing ongoing health challenges. The use of mRNA technology for seasonal flu could also encourage future innovations in vaccine development, potentially leading to more agile responses to other emerging diseases.

Following the rollout, the performance of mFlusiva will be monitored through ongoing studies to assess its long-term safety and efficacy. Future steps could include expanding the vaccine to younger age groups or evaluating its effectiveness against different influenza strains. This development marks a transition toward modern vaccination strategies aimed at improving health outcomes. As health systems continue to manage infectious diseases, mFlusiva provides an additional tool for the prevention of seasonal influenza.